This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Onyx Pharma: Kyprolis Is Still A Smokin' Hot Multiple Myeloma Drug

SAN FRANCISCO ( TheStreet) -- Onyx Pharmaceuticals (ONXX) pre-announced strong fourth quarter net sales of at least $43.4 million for its newly launched multiple myeloma drug Kyprolis.

Tacked on to previously reported third-quarter sales of $18.6 million, Kyprolis closed out 2012 with net sales exceeding $62 million, Onyx said during its presentation at the J.P. Morgan Healthcare Conference.

At this pace, Kyprolis is already well on it way towards topping Wall Street's 2013 consensus sales estimate of approximately $200 million. The FDA approved Kyprolis in July for the treatment of patients with relapsed or refractory multiple myeloma.

I got a chance to speak with Onyx CEO Tony Coles before his J.P. Morgan presentation. Here's some of what he had to say:

On the Kyprolis launch and goals for 2013:

"We're really pleased with the U.S. launch. It's got off to a good start with rapid penetration in patients and accounts in the third quarter and that's continued through the end of the year. The next question for us is what we do in Europe and the rest-of-world markets.

"In Europe, approval is contingent on the FOCUS and ASPIRE trials... We could file on either one of these studies. We should have interim results in the second half of the year from the FOCUS trial and results from ASPIRE as early as the fourth quarter."

[The FOCUS trial is evaluating single-agent Kyprolis in relapsed/refractory multiple myeloma patients. The ASPIRE trial compares Kyprolis, <b>Celgene's</b> <span class=" TICKERFLAT">(<a href="/quote/CELG.html">CELG</a> - <a href=";ticker=CELG">Get Report</a><a class=" arrow" href="/quote/CELG.html"><span class=" tickerChange" id="story_CELG"></span></a>)</span> Revlimid and low-dose dexamethasone against Revlimid and low-dose dex, also in relapsed/refractory multiple myeloma patients.]

On the possibility of compendia listing for Kyprolis in front-line multiple myeloma:

"It's probably too early. We have good phase II data [in front-line multiple myeloma] but to date, we've had no conversations about compendia listing. It may be too early to have those conversations based just on phase II data. But with that said, investigators are really excited about the role Kyprolis may play in the front-line setting.

On R&D priorities and the potential for expanding the company's pipeline:

"The key to Onyx's success has been maintaining an optionality in the pipeline. We've done this through acquisitions, in-licensing and option agreements since we don't have internal development capabilities. Looking forward, I think people can continue to expect us to look at a range of transactions to expand our pipeline.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
CELG $117.97 0.85%
AAPL $109.50 -1.16%
FB $92.47 0.08%
GOOG $639.16 -0.50%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs